Category - Developments

Developments

Kardium raises $115-million financing round

Closely-held Kardium raised $115-million in a new financing round led by Fidelity Management & Research, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates. The new...

January 25, 2021

Developments

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

The FDA approved Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. LUPKYNIS is...

January 25, 2021

Developments

Soricimed approach to COVID-19 being validated by other researchers

Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma. The peptide...

January 25, 2021

Developments

Think Research to acquire MDBriefCase Group

Think Research (TSXV:THNK) agreed to acquire closely-held MDBriefCase Group, a portfolio company of Persistence Capital Partners, for $25.3-million, mostly in stock. The transaction, which is expected to close in the...

January 20, 2021

Developments

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...

January 15, 2021

Developments

Neuronetics Q4 preliminary revenue tops guidance

Neuronetics (NASDAQ:STIM) reported preliminary unaudited revenue for the fourth quarter of 2020 between $15-million and $15.5-million, compared with previous guidance of $13-million and $13.5-million. “During the...

January 13, 2021

Developments

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

Diabeloop and SFC Fluidics agreed to develop a Type 1 diabetes system that integrates SFC’s alternate controller-enabled (ACE) insulin pod into Diabeloop’s automated insulin delivery solution in the U.S. The new...

January 11, 2021

Developments

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Closely-held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...

January 7, 2021

Developments

IntelGenx receives first purchase order for CBD filmstrips from Heritage Cannabis

IntelGenx (TSXV:IGX; OTCQB:IGXT) executed of a definitive supply agreement with Heritage Cannabis Holdings (CSE:CANN; OTCQX:HERTF) to manufacture and supply filmstrip products containing 10 mg of cannabidiol (CBD) using...

January 7, 2021

Developments

Profound Medical Q4 preliminary revenue beats consensus estimates

Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...

January 6, 2021

Category - Developments

Kardium raises $115-million financing round

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

Soricimed approach to COVID-19 being validated by other researchers

Think Research to acquire MDBriefCase Group

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Neuronetics Q4 preliminary revenue tops guidance

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

IntelGenx receives first purchase order for CBD filmstrips from Heritage Cannabis

Profound Medical Q4 preliminary revenue beats consensus estimates

General

More